Federal Register / Vol. 75, No. 20 / Monday, February 1, 2010 / Notices 5093 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, Innovative 

Technologies Development. 

Date: March 10–11, 2010. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Jeffrey E. DeClue, PhD, 

Scientific Review Officer, Special Review 

and Logistics Branch, Division of Extramural 

Activities, National Cancer Institute, NIH, 

6116 Executive Boulevard, Room 8059, 

Bethesda, MD 20892–8329, 301–496–7904, 

decluej@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, EDRN 

Biomarker Development Labs (U01). 

Date: March 10–11, 2010. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott, 5151 Pooks Hill 

Road, Bethesda, MD 20814. 

Contact Person: Sherwood Githens, PhD, 

Scientific Review Officer, Special Review 

and Logistics Branch, Division of Extramural 

Activities, National Cancer Institute, 6116 

Executive Blvd. Room 8146, Bethesda, MD 

20892, 301–435–1822, 

githenss@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; 

Development of Anticancer Agents. 

Date: March 24–26, 2010. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: Bethesda North Marriott Hotel & 

Conference Center, 5701 Marinelli Road, 

Bethesda, MD 20852. 

Contact Person: Joyce C. Pegues, PhD, 

Scientific Review Officer, Special Review 

and Logistics Branch, Division of Extramural 

Activities, NIH National Cancer Institute, 

6116 Executive Boulevard, Room 7149, 

Bethesda, MD 20892–8329, 301–594–1286, 

peguesj@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Cancer 

Nanotechnology Platform Partnerships. 

Date: March 31–April 1, 2010. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda North Marriott Hotel & 

Conference Center, Montgomery County 

Conference Center Facility, 5701 Marinelli 

Road, North Bethesda, MD 20852. 

Contact Person: Savvas C Makrides, PhD, 

Scientific Review Officer, Special Review 

and Logistics Branch, Division of Extramural 

Activities, National Cancer Institute, NIH, 

6116 Executive Blvd., Rm 8053, Bethesda, 

MD 20892, 301–496–7421, 

makridessc@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, Small 

Grants Program for Cancer Epidemiology. 

Date: April 15–16, 2010. 

Time: 8:30 a.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Legacy Hotel and Meeting Center, 

1775 Rockville Pike, Rockville, MD 20852. 

Contact Person: Joyce C. Pegues, PhD, 

Scientific Review Officer, Special Review 

and Logistics Branch, Division of Extramural 

Activities, National Cancer Institute, NIH, 

6116 Executive Boulevard, Room 7149, 

Bethesda, MD 20892–8329, 301–594–1286, 

peguesj@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: January 25, 2010. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–2030 Filed 1–29–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Initial 

Review Group, Neurological Sciences and 

Disorders B. 

Date: February 25–26, 2010. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: US Grant Hotel, 326 Broadway, San 

Diego, CA 92101. 

Contact Person: Ernest W Lyons, PhD, 

Scientific Review Officer, Scientific Review 

Branch, NINDS/NIH/DHHS, Neuroscience 

Center, 6001 Executive Blvd., Suite 3208, 

MSC 9529, Bethesda, MD 20892–9529, 301– 

496–4056. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Initial 

Review, Group Neurological Sciences and 

Disorders A. 

Date: March 3, 2010. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Argonaut Hotel, 495 Jefferson Street, 

San Francisco, CA 94109. 

Contact Person: Richard D. Crosland, PhD, 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Research, 

NINDS/NIH/DHHS, Neuroscience Center, 

6001 Executive Blvd., Suite 3208, MSC 9529, 

Bethesda, MD 20892–9529, 301–496–9223. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: January 25, 2010. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–1932 Filed 1–29–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Notice of Meeting 

In accordance with section 10(d) of 

the Federal Advisory Committee Act (5 

U.S.C., Appendix 2), announcement is 

made of a Health Care Policy and 

Research Special Emphasis Panel (SEP) 

meeting. 

A Special Emphasis Panel is a group 

of experts in fields related to health care 

research who are invited by the Agency 

for Healthcare Research and Quality 

(AHRQ), and agree to be available, to 

conduct on an as-needed basis, 

scientific reviews of applications for 

AHRQ support. Individual members of 

the Panel do not attend regularly 

scheduled meetings and do not serve for 

fixed terms or a long period of time. 

Rather, they are asked to participate in 

particular review meetings which 

require their type of expertise. 

Substantial segments of the upcoming 

SEP meeting listed below will be closed 

to the public in accordance with the 

Federal Advisory Committee Act, 

section 10(d) of 5 U.S.C., Appendix 2 

and 5 U.S.C. 552b (c)(6). Grant 

applications for the ARRA: Limited 

Competition ‘‘Electronic Data Methods’’ 

(U13) applications are to be reviewed 

and discussed at this meeting. These 

discussions are likely to reveal personal 

information concerning individuals 

associated with the applications. This 

information is exempt from mandatory 


jlentini on DSKJ8SOYB1PROD with NOTICES
5094 Federal Register / Vol. 75, No. 20 / Monday, February 1, 2010 / Notices 

disclosure under the above-cited 

statutes. 

SEP Meeting on: ARRA: Limited 

Competition ‘‘Electronic Data Methods’’ 

(U13). 

Date: February 26, 2010 (Open on February 

26 from 8 a.m. to 8:15 a.m. and closed for the 

remainder of the meeting). 

Place: Marriott Bethesda North Hotel & 

Conference Center, 5701 Marinelli Road, 

Forest Glen Conference Room, Bethesda, 

Maryland 20852. 

Contact Person: Anyone wishing to obtain 

a roster of members, agenda or minutes of the 

non-confidential portions of this meeting 

should contact Mrs. Bonnie Campbell, 

Committee Management Officer, Office of 

Extramural Research, Education and Priority 

Populations, AHRQ, 540 Gaither Road, Room 

2038, Rockville, Maryland 20850, Telephone 

(301) 427–1554. 

Agenda items for this meeting are subject 

to change as priorities dictate. 

Dated: January 21, 2010. 

Carolyn M. Clancy, 

Director. 

[FR Doc. 2010–1902 Filed 1–29–10; 8:45 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Notice of Meeting 

In accordance with section 10(d) of 

the Federal Advisory Committee Act (5 

U.S.C., Appendix 2), announcement is 

made of a Health Care Policy and 

Research Special Emphasis Panel (SEP) 

meeting. 

A Special Emphasis Panel is a group 

of experts in fields related to health care 

research who are invited by the Agency 

for Healthcare Research and Quality 

(AHRQ), and agree to be available, to 

conduct on an as needed basis, 

scientific reviews of applications for 

AHRQ support. Individual members of 

the Panel do not attend regularlyscheduled meetings and do not serve for 

fixed terms or a long period of time. 

Rather, they are asked to participate in 

particular review meetings which 

require their type of expertise. 

Substantial segments of the upcoming 

SEP meeting listed below will be closed 

to the public in accordance with the 

Federal Advisory Committee Act, 

section 10(d) of 5 U.S.C., Appendix 2 

and 5 U.S.C. 552b(c)(6). Grant 

applications for the Transforming 

Primary Care (Ri 8) applications are to 

be reviewed and discussed at this 

meeting. These discussions are likely to 

reveal personal information concerning 

individuals associated with the 

applications. This information is 

exempt from mandatory disclosure 

under the above-cited statutes. 

SEP Meeting on: Transforming Primary 

Care (Ri 8). 

Date: March 9–10, 2010 (Open on March 9 

from 8:30 a.m. to 8:45 a.m. and closed for the 

remainder of the meeting). 

Place: Doubletree Hotel & Executive 

Meeting Center, 8120 Wisconsin Avenue, 

Conference Room TBD, Bethesda, Maryland 

20852. 

Contact Person: Anyone wishing to obtain 

a roster of members, agenda or minutes of the 

nonconfidential portions of this meeting 

should contact Mrs. Bonnie Campbell, 

Committee Management Officer, Office of 

Extramural Research, Education and Priority 

Populations, AHRQ, 540 Gaither Road, Room 

2038, Rockville, Maryland 20850, Telephone 

(301) 427–1554. 

Agenda items for this meeting are 

subject to change as priorities dictate. 

Dated: January 25, 2010. 

Carol M. Clancy, 

Director. 

[FR Doc. 2010–1900 Filed 1–29–10; 8:45 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Advisory Committee on Immunization 

Practices (ACIP) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC), 

announces the following meeting of the 

aforementioned committee: 

Times and Dates 

8 a.m.–6 p.m., February 24, 2010. 

8 a.m.–3 p.m., February 25, 2010. 

Place: CDC, Tom Harkin Global 

Communications Center, 1600 Clifton Road, 

NE., Building 19, Kent ‘‘Oz’’ Nelson 

Auditorium, Atlanta, Georgia 30333. 

Status: Open to the public, limited only by 

the space available. 

Purpose: The committee is charged with 

advising the Director, CDC, on the 

appropriate uses of immunizing agents. In 

addition, under 42 U.S.C. 1396s, the 

committee is mandated to establish and 

periodically review and, as appropriate, 

revise the list of vaccines for administration 

to vaccine-eligible children through the 

Vaccines for Children (VFC) program, along 

with schedules regarding the appropriate 

periodicity, dosage, and contraindications 

applicable to the vaccines. 

Matters To Be Discussed: The agenda will 

include discussions on; Human 

Papillomavirus (HPV) Vaccines; 13–Valent 

Pneumococcal Conjugate Vaccine; Influenza 

Vaccines; Rotavirus Vaccines; Vaccine 

Supply Update; Meningococcal Vaccines; 

Evidence Based Recommendations; Hepatitis 

B vaccination for diabetics. 

Agenda items are subject to change as 

priorities dictate. 

Contact Person for More Information: 

Antonette Hill, Immunization Services 

Division, National Center for Immunization 

and Respiratory Diseases, CDC, 1600 Clifton 

Road, NE., Mailstop E–05, Atlanta, Georgia 

30333, telephone (404)639–8836, fax 

(404)639–8905. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities for 

both the CDC and ATSDR. 

Dated: January 22, 2010. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2010–2043 Filed 1–29–10; 8:45 am] 

BILLING CODE 4160–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Privacy Act of 1974; Report of an 

Altered System of Records 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services (HHS). 

ACTION: Notice of an Altered System of 

Records (SOR). 

SUMMARY: In accordance with the 

requirements of the Privacy Act of 1974, 

the Health Resources and Services 

Administration (HRSA) is publishing 

notice of a proposal to alter the system 

of records for the Health Education 

Assistance On-Line Processing System 

(HOPS), 09–15–0044. 

The purposes of these alterations are 

to update the location of this system and 

the system manager, to modify routine 

use number 6, correct typographical 

errors, and to add routine use number 

17 related to notification of breaches in 

security or confidentiality of records 

maintained in the system. In addition, 

the section for Policies and Practices for 

Storing, Retrieving, Accessing, 

Retaining and Disposing of Records in 

the System was updated. The ‘‘Authority 

for Maintenance of System’’ provision 

has been modified to reference Section 

702 of the Public Health Service Act [42 

U.S.C. Section 292a], as amended, and 

to add the Debt Collection Improvement 

Act (31 U.S.C. Sections 3701 and 3711– 

3720E). Lastly, the ‘‘Disclosure to 

Consumer Reporting Agencies’’ 

provision was modified to reference the 

definition of a ‘‘consumer reporting 


jlentini on DSKJ8SOYB1PROD with NOTICES